Amyris, Inc. has secured a major milestone in biotechnology with a newly patented method for the biological synthesis of target compounds. This innovation focuses on their award-winning patent, titled ‘Microbial production of cannabinoids’. The patent describes modifying host cells to express specific enzymes of a biosynthetic pathway, enabling the efficient microbial generation of complex compounds.

Outstanding Invention in Biotechnology

This breakthrough has won Swanson Reed’s Patent of the Month in the Biotechnology, Chemical Engineering, and Nanotechnology industry for January 2026. It was selected because it represents an outstanding invention that completely transforms how the industry approaches the scalable manufacturing of cannabinoids.

Patent Abstract

The compositions and methods of the disclosure can be used to produce a cannabinoid in a host cell, such as a yeast cell. For example, the disclosure features host cells (e.g., yeast cells) modified to express one or more enzymes of a cannabinoid biosynthetic pathway, such as an acyl activating enzyme (AAE), a tetraketide synthase (TKS), a cannabigerolic acid synthase (CBGaS), and/or an olivetolic acid cyclase (OAC).

How This Innovation Meets U.S. R&D Tax Credit Rules

The development of this patented technology strongly aligns with the IRS Four-Part Test required to qualify for the U.S. Research and Development (R&D) Tax Credit:

• Permitted Purpose (New or Improved Business Component): The research was undertaken to develop a fundamentally new, highly efficient biological process for manufacturing cannabinoids, moving away from traditional agricultural extraction.
• Technological in Nature: The development process fundamentally relies on the hard sciences—specifically molecular biology, genetics, and chemical engineering.
• Elimination of Uncertainty: At the onset of the project, Amyris faced significant technological uncertainty regarding which specific combinations of enzymes (AAE, TKS, CBGaS, OAC) could be successfully integrated and expressed within a yeast host cell while maintaining cellular viability and achieving high yields.
• Process of Experimentation: The researchers engaged in systematic trial and error, modifying genetic sequences, testing various yeast strains, and analyzing the metabolic outputs using advanced analytical chemistry to optimize the biosynthetic pathway.

3 Practical Applications Qualifying for R&D Tax Credits

Companies utilizing or building upon this patent could claim R&D tax credits through the following practical applications:

1. Designing and Scaling Fermentation Bioreactors: Engineering specific bioreactor environments (experimenting with dissolved oxygen, pH levels, temperature, and specialized nutrient feeds) to maximize the output of the engineered yeast cells. This involves systematic experimentation to overcome the technological uncertainties of scaling up from lab-grade to commercial-grade production.
2. Synthesizing Rare and Novel Cannabinoids: Conducting further genetic experiments on the established pathway to produce rare cannabinoids (such as CBG or THCV) that exist only in trace amounts in nature. Evaluating different gene expressions and resolving biological uncertainties to create these distinct derivatives qualifies as experimental R&D.
3. Developing Downstream Purification Protocols: Creating innovative chemical engineering extraction techniques to effectively, cleanly, and economically separate the secreted cannabinoids from the complex yeast fermentation broth. Testing new solvent combinations or filtration technologies to achieve pharmaceutical-grade purity is a distinct process of experimentation.